GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Simris Alg AB (OSTO:SIMRIS B) » Definitions » COGS-to-Revenue

Simris Alg AB (OSTO:SIMRIS B) COGS-to-Revenue : 0.38 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Simris Alg AB COGS-to-Revenue?

Simris Alg AB's Cost of Goods Sold for the three months ended in Mar. 2024 was kr0.20 Mil. Its Revenue for the three months ended in Mar. 2024 was kr0.52 Mil.

Simris Alg AB's COGS to Revenue for the three months ended in Mar. 2024 was 0.38.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Simris Alg AB's Gross Margin % for the three months ended in Mar. 2024 was 62.24%.


Simris Alg AB COGS-to-Revenue Historical Data

The historical data trend for Simris Alg AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simris Alg AB COGS-to-Revenue Chart

Simris Alg AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.80 2.27 1.34 1.18 0.54

Simris Alg AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.93 -1.39 0.79 0.38

Simris Alg AB COGS-to-Revenue Calculation

Simris Alg AB's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.347 / 4.354
=0.54

Simris Alg AB's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.196 / 0.519
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Simris Alg AB  (OSTO:SIMRIS B) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Simris Alg AB's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.196 / 0.519
=62.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Simris Alg AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Simris Alg AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Simris Alg AB (OSTO:SIMRIS B) Business Description

Traded in Other Exchanges
Address
Herrestadsvagen 24A, Hammenhog, SWE, 276 50
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.

Simris Alg AB (OSTO:SIMRIS B) Headlines

No Headlines